GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clal Biotechnology Industries Ltd (XTAE:CBI) » Definitions » Debt-to-Revenue

Clal Biotechnology Industries (XTAE:CBI) Debt-to-Revenue : N/A (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Clal Biotechnology Industries Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Clal Biotechnology Industries's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₪5.44 Mil. Clal Biotechnology Industries's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₪30.32 Mil. Clal Biotechnology Industries's annualized Revenue for the quarter that ended in Dec. 2023 was ₪0.00 Mil.


Clal Biotechnology Industries Debt-to-Revenue Historical Data

The historical data trend for Clal Biotechnology Industries's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clal Biotechnology Industries Debt-to-Revenue Chart

Clal Biotechnology Industries Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 37.55 52.15 99.27 343.82

Clal Biotechnology Industries Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 8.26 183.66 N/A N/A

Competitive Comparison of Clal Biotechnology Industries's Debt-to-Revenue

For the Biotechnology subindustry, Clal Biotechnology Industries's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clal Biotechnology Industries's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clal Biotechnology Industries's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Clal Biotechnology Industries's Debt-to-Revenue falls into.



Clal Biotechnology Industries Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Clal Biotechnology Industries's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(5.441 + 30.316) / 0.104
=343.82

Clal Biotechnology Industries's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(5.441 + 30.316) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.


Clal Biotechnology Industries Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Clal Biotechnology Industries's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Clal Biotechnology Industries (XTAE:CBI) Business Description

Traded in Other Exchanges
N/A
Address
Azrieli Center, Triangle Building, 45th Floor, Tel Aviv, ISR, 67023
Clal Biotechnology Industries Ltd is a life sciences investment company. The company invests in companies ranging from seed to maturity, both public and private. Its portfolio of investments includes from heavy industry to biotechnology, hi-tech and energy companies.

Clal Biotechnology Industries (XTAE:CBI) Headlines

From GuruFocus

Should We Devote Attention to Market Factors?

By Grahamites Grahamites 08-25-2015

Dollar Cost Average on CBI

By Jonathan Poland Jonathan Poland 08-17-2017

CB&I Announces DPC Technology Award in China

By PRNewswire PRNewswire 04-03-2018

Seeking Value in the Construction Industry

By Mark Yu Mark Yu 07-03-2017

Van Den Berg Reduces Position in 5-Star Company

By Kyle Ferguson Kyle Ferguson 01-25-2016

McDermott Announces Ethylene Furnace Award in Indonesia

By PRNewswire PRNewswire 01-24-2019